In patients with hepatocellular carcinoma (HCC) and non-small-cell lung cancer (NSCLC), aberrant c-Met alternations like point mutations, amplification, and fusion are associated with drug resistance, aggressiveness, and poor prognosis of the patients [9,13,14,15,16]. The gene discussed is MET; the disease is hepatocellular carcinoma.